Bioanalysis in clinical development of tasquinimod using liquid chromatography/tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 30, 2011, Pages 3401-3406

  Hansson, G P ^a   Olin, M ^a   Svanstrom C ^a   Svensson, L D ^a   Sennbro, C J ^a  

^a Active Biotech Research AB   (Sweden)

Author keywords

Bioanalysis; Incurred sample stability; Internal standard; LC MS; Prostate cancer; Stable isotope; Tasquinimod

Indexed keywords

BIOANALYSIS; INCURRED SAMPLE STABILITY; INTERNAL STANDARDS; LC-MS; PROSTATE CANCERS; STABLE ISOTOPES; TASQUINIMOD;

ACETONITRILE; DISEASES; ISOTOPES; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; PATIENT TREATMENT; PLASMA STABILITY;

EXTRACTION;

TASQUINIMOD;

ACCURACY; ARTICLE; DRUG BLOOD LEVEL; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DYNAMICS; HUMAN; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HUMANS; MALE; PROSTATIC NEOPLASMS; QUINOLINES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 80555149304     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.09.013     Document Type: Article

References (13)

1. Isaacs J.T., Pili R., Qian D.Z., Dalrymple S.L., Garrison J.B., Kyprianou N., Björk A., Olsson A., Leanderson T. Prostate 2006, 66:1768. 10.1002/pros.20509.
2. Dalrymple S.L., Becker R.E., Isaacs J.T. Prostate 2007, 67:790. 10.1002/pros.20573.
3. Isaac J.T. Expert Opin. Investig. Drugs 2010, 19:1235. 10.1517/13543784.2010.514262.
4. Olsson A., Björk A., Vallon-Christersson J., Isaacs J.T., Leandersson T. Mol. Cancer 2010, 9:107. 10.1186/1476-4598-9-107.
5. Björk P., Björk A., Vogl T., Stenström M., Liberg D., Olsson A., Roth J., Ivars F., Leanderson T. PLoS Biol. 2009, 7:e97. 10.1371/journal.pbio.1000097.
6. Bratt O., Häggman M., Ahlgren G., Nordle Ö., Björk A., Damber J.E. Br. J. Cancer 2009, 101:1233. 10.1038/sj.bjc.6605322.
7. Armstrong A.J., Haggman M., Stadler W.M., Gingrich J.R., Assikis V.J., Nordle O., Forsberg G., Carducci M.A., Pili R. J. Clin. Oncol. 2011, 29:7. Available at: http://meeting.ascopubs.org/cgi/content/abstract/29/7_suppl/126.
8. Edman K., Eriksson B., Svensson L., Gunnarsson P.O. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 785:311. 10.1016/S1570-0232(02)00926-1.
9. Sennbro C.J., Olin M., Edman K., Hansson G., Gunnarsson P.O., Svensson L. Rapid Commun. Mass Spectrom. 2006, 20:3313. 10.1002/rcm.2730.
10. US Food and drug administration (FDA) Center for Drug evaluation and Research. Guidance for Industry: Bioanalytical Method Validation 2001.
11. EMA Guideline on Bioanalytical Method Validation 2011, Committee for Medicinal Products for Human Use (CHMP).
12. Timmerman P., Luedtke S., van Amsterdam P., Brudny-Kloeppel M., Lausecker B. Bioanalysis 2009, 1:1049. 10.4155/BIO.09.108.
13. Fast D.M., Kelley M., Viswanathan C.T., O'Shaughnessy J., King S.P., Chaudhary A., Weiner R., DeStefano A.J., Tang D. AAPS J. 2009, 2:238.